Smith – Management of Refractory Distributive Shock | Maryland CC Project

In this monologue, Dr. Lane Smith, a critical care medicine specialist, discusses the management of refractory distributive shock, focusing on angiotensin 2 (AT2) as a novel therapeutic. He reviews the epidemiology and history of distributive shock, emphasizing the importance of addressing organ dysfunction. He also covers the evolution of vasopressor use, highlighting norepinephrine as the first-line agent. The discussion includes a detailed analysis of the ATHOS-3 trial, its findings, and limitations, as well as the results of a study conducted at the University of Michigan on AT2. Dr. Smith concludes with insights on other salvage vasopressors like methylene blue and B12, and their implications in treating distributive shock.

Outlines

Part 1: Introduction and Initial Management

Part 2: Angiotensin II: Trials and Results

Part 3: Real-World Evidence and Future Directions

Part 4: Conclusion

Sign in to continue reading, translating and more.

Continue

Smith – Management of Refractory Distributive Shock

Maryland CC Project

Part 1: Introduction and Initial Management

Introduction to Refractory Distributive Shock and Angiotensin II

Assessing and Managing Refractory Distributive Shock

Part 2: Angiotensin II: Trials and Results

Angiotensin II: Mechanism, Pilot Data, and the ATHOS-3 Trial Design

ATHOS-3 Trial Results and Post-Hoc Analyses

Part 3: Real-World Evidence and Future Directions

University of Michigan Study: Design and Patient Population

University of Michigan Study: Outcomes and Analysis

Implications, Future Research, and Other Salvage Vasopressors

Part 4: Conclusion

Conclusion

Smith – Management of Refractory Distributive Shock

Maryland CC Project

Part 1: Introduction and Initial Management

00:00Introduction to Refractory Distributive Shock and Angiotensin II

Introduction to Refractory Distributive Shock and Angiotensin II

05:45Assessing and Managing Refractory Distributive Shock

Assessing and Managing Refractory Distributive Shock

Part 2: Angiotensin II: Trials and Results

15:52Angiotensin II: Mechanism, Pilot Data, and the ATHOS-3 Trial Design

Angiotensin II: Mechanism, Pilot Data, and the ATHOS-3 Trial Design

25:28ATHOS-3 Trial Results and Post-Hoc Analyses

ATHOS-3 Trial Results and Post-Hoc Analyses

Part 3: Real-World Evidence and Future Directions

32:42University of Michigan Study: Design and Patient Population

University of Michigan Study: Design and Patient Population

41:13University of Michigan Study: Outcomes and Analysis

University of Michigan Study: Outcomes and Analysis

47:02Implications, Future Research, and Other Salvage Vasopressors

Implications, Future Research, and Other Salvage Vasopressors

Part 4: Conclusion

50:32Conclusion

Conclusion